{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:04:52Z","timestamp":1766023492352,"version":"3.48.0"},"reference-count":37,"publisher":"e-Century Publishing Corporation","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/aafk9855","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T04:18:11Z","timestamp":1748578691000},"page":"2111-2126","source":"Crossref","is-referenced-by-count":0,"title":["A short-term prognostic model based on urinary IgG, CO2CP and TP for newly diagnosed multiple myeloma"],"prefix":"10.62347","volume":"15","author":[{"given":"Jiaxiang","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK and Libby EN. Diagnosis and management of multiple myeloma: a review. JAMA 2022; 327: 464-477.","journal-title":"JAMA"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1007\/s10238-023-00992-8","article-title":"A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients","volume":"23","author":"Ren","year":"2023","unstructured":"Ren L, Xu J, Li J, Xu T, Yang Y, Wang W, Ren Y, Gu S, Chen C, Wei Z, Zhuang J, Wang Z, Ji L, Cheng L, Wang W, Cheng Z, Ke Y, Yuan L and Liu P. A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients. Clin Exp Med 2023; 23: 2583-2591.","journal-title":"Clin Exp Med"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD and Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30.","DOI":"10.3322\/caac.21590"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1038\/s41467-022-31430-0","article-title":"The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma","volume":"13","author":"JN","year":"2022","unstructured":"Vo JN, Wu YM, Mishler J, Hall S, Mannan R, Wang L, Ning Y, Zhou J, Hopkins AC, Estill JC, Chan WKB, Yesil J, Cao X, Rao A, Tsodikov A, Talpaz M, Cole CE, Ye JC; Multiple Myeloma Research Consortium; Bergsagel PL, Auclair D, Cho HJ, Robinson DR and Chinnaiyan AM. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun 2022; 13: 3750.","journal-title":"Nat Commun"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"PR","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I and Westin J. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from International Myeloma Working Group","volume":"33","author":"Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV and Moreau P. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015; 33: 2863-2869.","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project","volume":"40","author":"D&#x2019","year":"2022","unstructured":"D’Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall’Olio D, van de Donk N, Jackson G, Rocchi S, Salwender H, Bladé Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, Dürig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hernández Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M and Sonneveld P. Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY Project. J Clin Oncol 2022; 40: 3406-3418.","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3324\/haematol.2009.016329","article-title":"The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance","volume":"95","author":"FM","year":"2010","unstructured":"Ross FM, Chiecchio L, Dagrada G, Protheroe RK, Stockley DM, Harrison CJ, Cross NC, Szubert AJ, Drayson MT and Morgan GJ; UK Myeloma Forum. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica 2010; 95: 1221-1225.","journal-title":"Haematologica"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00277-019-03844-2","article-title":"Clinical impact of the CONUT score in patients with multiple myeloma","volume":"99","author":"Okamoto","year":"2020","unstructured":"Okamoto S, Ureshino H, Kidoguchi K, Kusaba K, Kizuka-Sano H, Sano H, Nishioka A, Yamaguchi K, Kamachi K, Itamura H, Yoshimura M, Yokoo M, Shindo T, Kubota Y, Ando T, Kojima K, Kawaguchi A, Sueoka E and Kimura S. Clinical impact of the CONUT score in patients with multiple myeloma. Ann Hematol 2020; 99: 113-119.","journal-title":"Ann Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","article-title":"Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013","volume":"88","author":"JR","year":"2013","unstructured":"Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A and Lacy MQ; Mayo Clinic. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc 2013; 88: 360-376.","journal-title":"Mayo Clin Proc"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1021587","DOI":"10.3389\/fcell.2022.1021587","article-title":"A prognostic model for patients with primary extramedullary multiple myeloma","volume":"10","author":"Zhang","year":"2022","unstructured":"Zhang L, Chen S, Wang W, Wang Y and Liang Y. A prognostic model for patients with primary extramedullary multiple myeloma. Front Cell Dev Biol 2022; 10: 1021587.","journal-title":"Front Cell Dev Biol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.3390\/nu15194210","article-title":"Nutritional status indices and monoclonal gammopathy of undetermined significance risk in the elderly population: findings from the National Health and Nutrition Examination Survey","volume":"15","author":"Li","year":"2023","unstructured":"Li L, Wu M, Yu Z and Niu T. Nutritional status indices and monoclonal gammopathy of undetermined significance risk in the elderly population: findings from the National Health and Nutrition Examination Survey. Nutrients 2023; 15: 4210.","journal-title":"Nutrients"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"109496","DOI":"10.1016\/j.intimp.2022.109496","article-title":"Hemoglobin, albumin, lymphocyte, and platelet (HALP) score and cancer prognosis: a systematic review and meta-analysis of 13,110 patients","volume":"114","author":"Xu","year":"2023","unstructured":"Xu H, Zheng X, Ai J and Yang L. Hemoglobin, albumin, lymphocyte, and platelet (HALP) score and cancer prognosis: a systematic review and meta-analysis of 13,110 patients. Int Immunopharmacol 2023; 114: 109496.","journal-title":"Int Immunopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/JIR.S390279","article-title":"Inflammatory and nutritional scoring system for predicting prognosis in patients with newly diagnosed multiple myeloma","volume":"16","author":"Zhang","year":"2023","unstructured":"Zhang L, Chen S, Wang W, Wang Y and Liang Y. Inflammatory and nutritional scoring system for predicting prognosis in patients with newly diagnosed multiple myeloma. J Inflamm Res 2023; 16: 7-17.","journal-title":"J Inflamm Res"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"766672","DOI":"10.3389\/fonc.2021.766672","article-title":"Are the derived indexes of peripheral whole blood cell counts (NLR, PLR, LMR\/MLR) clinically significant prognostic biomarkers in multiple myeloma? A systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2021","unstructured":"Zhang X, Duan J, Wen Z, Xiong H, Chen X, Liu Y, Liao K and Huang C. Are the derived indexes of peripheral whole blood cell counts (NLR, PLR, LMR\/MLR) clinically significant prognostic biomarkers in multiple myeloma? A systematic review and meta-analysis. Front Oncol 2021; 11: 766672.","journal-title":"Front Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.7150\/jca.69321","article-title":"A new prediction model integrated serum lipid profile for patients with multiple myeloma","volume":"13","author":"Wang","year":"2022","unstructured":"Wang H, Chen B, Shao R, Liu W, Xiong L, Li L and Lu Y. A new prediction model integrated serum lipid profile for patients with multiple myeloma. J Cancer 2022; 13: 1796-1807.","journal-title":"J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Balachandran VP, Gonen M, Smith JJ and DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol 2015; 16: e173-180.","DOI":"10.1016\/S1470-2045(14)71116-7"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/cncr.34641","article-title":"The prognostic role of 1q21 gain\/amplification in newly diagnosed multiple myeloma: the faster, the worse","volume":"129","author":"Wang","year":"2023","unstructured":"Wang Y, Xu J, Xu B, Li P, Yang Y, Wang W, Xu T, Maihemaiti A, Lan T, Wang P, Ren L, Zhou C, Aihemaiti X and Liu P. The prognostic role of 1q21 gain\/amplification in newly diagnosed multiple myeloma: the faster, the worse. Cancer 2023; 129: 1005-1016.","journal-title":"Cancer"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/ijlh.13958","article-title":"The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma","volume":"45","author":"Solmaz","year":"2023","unstructured":"Solmaz S, Uzun O, Sevindik OG, Demirkan F, Ozcan MA, Ozsan GH and Alacacıoglu I. The effect of haemoglobin, albumin, lymphocyte and platelet score on the prognosis in patients with multiple myeloma. Int J Lab Hematol 2023; 45: 13-19.","journal-title":"Int J Lab Hematol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"41370","DOI":"10.18632\/oncotarget.5629","article-title":"Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study","volume":"6","author":"Chen","year":"2015","unstructured":"Chen XL, Xue L, Wang W, Chen HN, Zhang WH, Liu K, Chen XZ, Yang K, Zhang B, Chen ZX, Chen JP, Zhou ZG and Hu JK. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. Oncotarget 2015; 6: 41370-41382.","journal-title":"Oncotarget"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/0002-9610(80)90246-9","article-title":"Prognostic nutritional index in gastrointestinal surgery","volume":"139","author":"Buzby","year":"1980","unstructured":"Buzby GP, Mullen JL, Matthews DC, Hobbs CL and Rosato EF. Prognostic nutritional index in gastrointestinal surgery. Am J Surg 1980; 139: 160-167.","journal-title":"Am J Surg"},{"key":"ref21","unstructured":"Ignacio de Ulíbarri J, González-Madroño A, de Villar NG, González P, González B, Mancha A, Rodríguez F and Fernández G. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp 2005; 20: 38-45."},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS and Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016; 17: e328-e346.","DOI":"10.1016\/S1470-2045(16)30206-6"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"805702","DOI":"10.3389\/fonc.2022.805702","article-title":"Development and validation of a novel prognostic model for overall survival in newly diagnosed multiple myeloma integrating tumor burden and comorbidities","volume":"12","author":"Jia","year":"2022","unstructured":"Jia S, Bi L, Chu Y, Liu X, Feng J, Xu L, Zhang T, Gu H, Yang L, Bai Q, Liang R, Tian B, Gao Y, Tang H and Gao G. Development and validation of a novel prognostic model for overall survival in newly diagnosed multiple myeloma integrating tumor burden and comorbidities. Front Oncol 2022; 12: 805702.","journal-title":"Front Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"6328","DOI":"10.1038\/s41598-021-85948-2","article-title":"Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer","volume":"11","author":"Nakamoto","year":"2021","unstructured":"Nakamoto S, Ikeda M, Kubo S, Yamamoto M, Yamashita T and Notsu A. Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer. Sci Rep 2021; 11: 6328.","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3233\/CBM-220451","article-title":"Comprehensive analysis and establishment of a prognostic model based on non-genetic predictors in multiple myeloma","volume":"38","author":"Lu","year":"2023","unstructured":"Lu W, Xu S, Tan S, Lu L, Luo M and Xiao M. Comprehensive analysis and establishment of a prognostic model based on non-genetic predictors in multiple myeloma. Cancer Biomark 2023; 38: 49-59.","journal-title":"Cancer Biomark"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Khosravi P, Abroun S, Kaviani S, Masoudifar S and Farahani HS. Calprotectin as new potential clinical marker for multiple myeloma. PLoS One 2023; 18: e0282841.","DOI":"10.1371\/journal.pone.0282841"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1080\/16078454.2022.2078040","article-title":"Prognostic role of controlling nutritional status score in hematological malignancies","volume":"27","author":"Zhang","year":"2022","unstructured":"Zhang Y, Chen Q, Lu C and Yu L. Prognostic role of controlling nutritional status score in hematological malignancies. Hematology 2022; 27: 653-658.","journal-title":"Hematology"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"140475","DOI":"10.1016\/j.bbapap.2020.140475","article-title":"Insights into predicting diabetic nephropathy using urinary biomarkers","volume":"1868","author":"Khan","year":"2020","unstructured":"Khan NU, Lin J, Liu X, Li H, Lu W, Zhong Z, Zhang H, Waqas M and Shen L. Insights into predicting diabetic nephropathy using urinary biomarkers. Biochim Biophys Acta Proteins Proteom 2020; 1868: 140475.","journal-title":"Biochim Biophys Acta Proteins Proteom"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"102473","DOI":"10.1016\/j.dsx.2022.102473","article-title":"The potential use of urinary transferrin, urinary adiponectin, urinary Retinol Binding Protein, and serum zinc alpha 2 glycoprotein levels as novel biomarkers for early diagnosis of diabetic nephropathy: a case-control study","volume":"16","author":"Kamel","year":"2022","unstructured":"Kamel MF, Nassar M, Elbendary A, Mohamed AGA, Abdullah MG, Gomaa HRA, Awad EMI, Mahmoud HH, Elfiki MA, Abdalla NH, Abd Elkareem RM, Soliman AS and Elmessiery RM. The potential use of urinary transferrin, urinary adiponectin, urinary Retinol Binding Protein, and serum zinc alpha 2 glycoprotein levels as novel biomarkers for early diagnosis of diabetic nephropathy: a case-control study. Diabetes Metab Syndr 2022; 16: 102473.","journal-title":"Diabetes Metab Syndr"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Mravljak M, Vizjak A, Ferluga D, Pajek J, Kovac D, Skoberne A, Ales Rigler A, Kveder R, Kosir A and Lindic J. Urinary immunoglobulin G to albumin ratio and N-Acetyl-Beta-D-Glucosaminidase as early predictors of therapeutic response in ANCA-associated glomerulonephritis. PLoS One 2013; 8: e81703.","DOI":"10.1371\/journal.pone.0081703"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.5551\/jat.64230","article-title":"Urinary immunoglobulin G is a novel biomarker for atherosclerotic burden in mild acute ischemic stroke patients","volume":"31","author":"Komatsu","year":"2024","unstructured":"Komatsu T, Okumura M, Kida H, Ozawa M, Mimori M, Kokubu T, Takahashi J, Kurihara S, Maku T, Motegi H, Takahashi M, Shiraishi T, Nakada R, Akiyama S, Kitagawa T, Sato T, Takatsu H, Sakai K, Umehara T, Omoto S, Murakami H, Mitsumura H and Iguchi Y. Urinary immunoglobulin G is a novel biomarker for atherosclerotic burden in mild acute ischemic stroke patients. J Atheroscler Thromb 2024; 31: 306-315.","journal-title":"J Atheroscler Thromb"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"850961","DOI":"10.3389\/fonc.2022.850961","article-title":"Cross-sectional and longitudinal associations between the serum G\\lobulin level, and renal impairment and all-cause deaths in chinese patients with newly diagnosed multiple myeloma","volume":"12","author":"Cheng","year":"2022","unstructured":"Cheng J, Sun J, Zhao Y, Li X, Jiang Y, Lv R, Li H and Chen J. Cross-sectional and longitudinal associations between the serum G\\lobulin level, and renal impairment and all-cause deaths in chinese patients with newly diagnosed multiple myeloma. Front Oncol 2022; 12: 850961.","journal-title":"Front Oncol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.3892\/etm.2017.4292","article-title":"Metabolic acidosis as a risk factor for the development of acute kidney injury and hospital mortality","volume":"13","author":"Hu","year":"2017","unstructured":"Hu J, Wang Y, Geng X, Chen R, Xu X, Zhang X, Lin J, Teng J and Ding X. Metabolic acidosis as a risk factor for the development of acute kidney injury and hospital mortality. Exp Ther Med 2017; 13: 2362-2374.","journal-title":"Exp Ther Med"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Uno S, Midorikawa S, Inoue K, Ichikawa D, Ito T, Kuroda J and Suzuki K. Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan. PLoS One 2023; 18: e0285947.","DOI":"10.1371\/journal.pone.0285947"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.31557\/APJCP.2022.23.9.2937","article-title":"Serum levels of interleukin-1β and disease progression in multiple myeloma patients: a case and control study","volume":"23","author":"Nobari S","year":"2022","unstructured":"Teimuri Nobari S, Rasmi Y and Khadem Ansari MH. Serum levels of interleukin-1β and disease progression in multiple myeloma patients: a case and control study. Asian Pac J Cancer Prev 2022; 23: 2937-2942.","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00277-023-05115-7","article-title":"Characteristics of inpatients with newly diagnosed multiple myeloma in hematology, nephrology, and orthopedic departments","volume":"102","author":"Zhang","year":"2023","unstructured":"Zhang Y, Pan J, Kang H, Peng S, Tung TH and Shen B. Characteristics of inpatients with newly diagnosed multiple myeloma in hematology, nephrology, and orthopedic departments. Ann Hematol 2023; 102: 801-809.","journal-title":"Ann Hematol"}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/5\/ajcr0161346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:00:10Z","timestamp":1766023210000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/5\/ajcr0161346.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":37,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/aafk9855","relation":{},"ISSN":["2156-6976"],"issn-type":[{"type":"electronic","value":"2156-6976"}],"subject":[],"published":{"date-parts":[[2025]]}}}